Compare · CI vs CSTL
CI vs CSTL
Side-by-side comparison of The Cigna Group (CI) and Castle Biosciences Inc. (CSTL): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both CI and CSTL operate in Medical Specialities (Health Care), so they compete in similar markets.
- CI is the larger of the two at $73.81B, about 69.0x CSTL ($1.07B).
- Over the past year, CI is down 5.5% and CSTL is up 58.6% - CSTL leads by 64.1 points.
- CSTL has been more active in the news (12 items in the past 4 weeks vs 8 for CI).
- CI has more recent analyst coverage (25 ratings vs 6 for CSTL).
- Company
- The Cigna Group
- Castle Biosciences Inc.
- Price
- -
- -
- Market cap
- $73.81B
- $1.07B
- 1M return
- -5.86%
- +42.01%
- 1Y return
- -5.52%
- +58.60%
- Industry
- Medical Specialities
- Medical Specialities
- Exchange
- NYSE
- NASDAQ
- IPO
- 2019
- News (4w)
- 8
- 12
- Recent ratings
- 25
- 6
The Cigna Group
Cigna Corporation provides insurance and related products and services in the United States. Its Evernorth segment provides a range of coordinated and point solution health services, including pharmacy, benefits management, care, and intelligence solutions to health plans, employers, government organizations, and health care providers. The company's U.S. Medical segment offers commercial products and services, including medical, pharmacy, behavioral health, dental, vision, health advocacy programs, and other products and services for insured and self-insured customers; Medicare Advantage, Medicare Supplement, and Medicare Part D plans for seniors, as well as Medicaid plans; and individual health insurance plans to on and off the public exchanges. Its International Markets segment offers health coverage, hospitalization, dental, critical illness, personal accident, term life, medical cost containment, and variable universal life products, as well as health care benefits to mobile employees of multinational organizations. The company distributes its products and services through insurance brokers and consultants; directly to employers, unions and other groups, or individuals; and private and public exchanges. The company was founded in 1792 and is headquartered in Bloomfield, Connecticut.
Castle Biosciences Inc.
Castle Biosciences, Inc., a commercial-stage dermatological cancer company, focuses to provide diagnostic and prognostic solutions for dermatological cancers. Its lead product is DecisionDx-Melanoma, a multi-gene expression profile (GEP) test to identify high-risk patients with stage I and II melanomas based on biological information from 31 genes within their tumor tissue. The company also offers DecisionDx-UM test, a proprietary GEP test that predicts the risk of metastasis for patients with uveal melanoma, a rare eye cancer; DecisionDx-SCC, a proprietary 40-gene expression profile test that uses an individual patient's tumor biology to predict individual risk of squamous cell carcinoma metastasis for patients with one or more risk factors; and DecisionDx DiffDx-Melanoma, a proprietary GEP test for suspicious pigmented lesions. It offers test services through physicians and their patients. The company was founded in 2007 and is headquartered in Friendswood, Texas.
Latest CI
- Cigna Healthcare Connects Medical and Supplemental Benefits To Help People Better Manage Unexpected Health Costs
- SEC Form 4 filed by Officer Holgerson Bryan
- Officer Jones Nicole S sold $748,516 worth of shares (2,677 units at $279.61) as part of a pre-agreed trading plan, decreasing direct ownership by 9% to 25,880 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- Officer Jones Nicole S exercised 15,346 shares at a strike of $192.02 and sold $5,369,584 worth of shares (19,436 units at $276.27) as part of a pre-agreed trading plan, decreasing direct ownership by 13% to 28,557 units (SEC Form 4)
- SEC Form 144 filed by The Cigna Group
- The Cigna Group downgraded by Jefferies with a new price target
- The Cigna Group downgraded by Raymond James with a new price target
- SEC Form 10-Q filed by The Cigna Group
- The Cigna Group filed SEC Form 8-K: Results of Operations and Financial Condition, Financial Statements and Exhibits
Latest CSTL
- Castle Biosciences to Participate in Upcoming Investor Conferences
- Chief Commercial Officer Juvenal Tobin W sold $51,191 worth of shares (1,730 units at $29.59) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 75,964 units (SEC Form 4)
- Chief Financial Officer Stokes Frank sold $741,511 worth of shares (24,908 units at $29.77), decreasing direct ownership by 41% to 35,177 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 1,100 shares at a strike of $2.39 and sold $217,105 worth of shares (7,232 units at $30.02) as part of a pre-agreed trading plan (SEC Form 4)
- Castle Biosciences Approved for Dual Listing on Nasdaq Texas
- SEC Form 144 filed by Castle Biosciences Inc.
- SEC Form 8-A12B filed by Castle Biosciences Inc.
- Chief Commercial Officer Juvenal Tobin W sold $49,945 worth of shares (1,301 units at $38.39) as part of a pre-agreed trading plan, decreasing direct ownership by 2% to 77,694 units (SEC Form 4)
- Pres. & Chief Exec. Officer Maetzold Derek J exercised 22,902 shares at a strike of $2.39 and sold $1,212,230 worth of shares (39,016 units at $31.07) as part of a pre-agreed trading plan (SEC Form 4)
- Chief Operating Officer Oelschlager Kristen M sold $255,622 worth of shares (8,586 units at $29.77) as part of a pre-agreed trading plan, decreasing direct ownership by 39% to 13,288 units (SEC Form 4)